Cencora

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +50

Cencora Names New CFO and Reaffirms 2026 Outlook

AI-generated analysis

πŸ‘©β€πŸ’Ό Cencora appointed Eva C. Boratto as Executive Vice President and Chief Financial Officer, effective June 29, 2026.

πŸ”„ She succeeds retiring CFO James F. Cleary, who will stay in an advisory role through year-end to ensure continuity.

πŸ₯ Boratto brings extensive experience from senior roles at Bath & Body Works, CVS Health, and Merck.

πŸ’° Cencora reaffirmed its adjusted diluted earnings per share guidance of $17.70 to $17.90 for fiscal 2026.

πŸ“ˆ The company reiterated long-term targets for adjusted operating income growth of 7% to 10%.

πŸš€ Management also maintained an adjusted EPS growth target of 10% to 14% for the long term.

🀝 The CFO transition is not expected to disrupt financial performance or shareholder value creation plans.

πŸ“Š Analysts currently rate Cencora stock as a Buy with a $331.00 price target.

βš–οΈ AI Analyst Spark rates COR as Neutral due to solid operations offset by balance-sheet leverage risk.

πŸ“‰ Technical indicators show a clear downtrend and weak momentum for the stock.

πŸ’΅ Valuation is considered a relative positive due to the low P/E ratio.

🌍 Cencora is ranked No. 10 on the Fortune 500 and generates over $300 billion in annual revenue.

πŸ“¦ The company operates as a critical intermediary between pharmaceutical manufacturers and healthcare providers.

πŸ”’ Its business model focuses on logistics, distribution, and ensuring secure delivery of healthcare products.

Bullish Signals
  • Cencora appointed Eva C. Boratto as new CFO, bringing extensive experience from senior roles at Bath & Body Works, CVS Health, and Merck to bolster its financial leadership.
  • The company reaffirmed adjusted diluted earnings per share guidance of $17.70 to $17.90 for fiscal 2026 following opportunistic share repurchases.
  • Management reiterated long-term targets for adjusted operating income growth of 7% to 10% and adjusted EPS growth of 10% to 14%, signaling confidence in sustained performance.
  • The CFO transition is not expected to disrupt financial performance or long-term value-creation plans for shareholders.
  • Cencora is ranked No. 10 on the Fortune 500 and generates more than $300 billion in annual revenue from its pharmaceutical-centric operations.
  • Valuation is a relative positive due to the low P/E ratio, despite other technical factors.
Risk Factors
  • Meaningful balance-sheet leverage risk is identified as a concern.
  • Recent free cash flow has deteriorated.
Full Analysis
Cencora (COR) announced on May 27, 2026, the appointment of Eva C. Boratto as its new Executive Vice President and Chief Financial Officer, effective June 29, 2026. She succeeds retiring CFO James F. Cleary, who will transition to an advisory role through year-end to ensure continuity. Boratto brings extensive experience from senior roles at Bath & Body Works, CVS Health, and Merck, along with audit committee chair positions at Mars and UPS, strengthening Cencora's financial leadership as it pursues its pharmaceutical-centric growth strategy. Alongside the leadership change, Cencora reaffirmed its adjusted diluted earnings per share guidance of $17.70 to $17.90 for fiscal 2026, a figure updated on May 21, 2026, following opportunistic share repurchases. The company reiterated long-term targets for adjusted operating income growth of 7% to 10% and adjusted EPS growth of 10% to 14%. This reaffirmed outlook signals management's confidence in the company's current trajectory and suggests that the CFO transition is not expected to disrupt financial performance or long-term value-creation plans for shareholders. Cencora is a leading global pharmaceutical solutions organization ranked No. 10 on the Fortune 500, generating more than $300 billion in annual revenue from its pharmaceutical-centric operations. Operating at the center of the global pharmaceutical supply chain, the company partners with drug innovators and care providers to facilitate market access to therapies and ensure secure delivery of pharmaceuticals and healthcare products for people and animals. Its business model positions it as a critical intermediary between manufacturers and providers, underpinning its scale-driven margins and ability to pursue steady, long-term earnings growth.